After Combining Assets, Takeda/Millennium Outline Oncology Strategy
With 13 oncology molecules in the clinic, R&D priorities include motesanib for lung cancer, an aurora A kinase inhibitor and expansion of Takeda’s prostate cancer expertise.
With 13 oncology molecules in the clinic, R&D priorities include motesanib for lung cancer, an aurora A kinase inhibitor and expansion of Takeda’s prostate cancer expertise.